Skip to content

H.R. 946 · 119th Congress (2025–2027)

ORPHAN Cures Act

This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition.

The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.

Show official title

To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 946’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. John Joyce (R-PA-13)
Cosponsors
18 cosponsors

9 original · 9 later

9 R · 9 D

  1. Rep. Gus M. Bilirakis (R-FL-12)· Original · Feb 4, 2025
  2. Rep. Donald G. Davis (D-NC-1)· Original · Feb 4, 2025
  3. Rep. Josh Gottheimer (D-NJ-5)· Original · Feb 4, 2025
  4. Rep. Richard Hudson (R-NC-9)· Original · Feb 4, 2025
  5. Rep. Kevin Hern (R-OK-1)· Original · Feb 4, 2025
  6. Rep. William R. Keating (D-MA-9)· Original · Feb 4, 2025
  7. Rep. Mariannette Miller-Meeks (R-IA-1)· Original · Feb 4, 2025
  8. Rep. Scott H. Peters (D-CA-50)· Original · Feb 4, 2025
  9. Rep. Shri Thanedar (D-MI-13)· Original · Feb 4, 2025
  10. Rep. Janelle S. Bynum (D-OR-5)· Later · Apr 7, 2025
  11. Rep. Thomas H. Kean, Jr. (R-NJ-7)· Later · Apr 7, 2025
  12. Rep. Lloyd Smucker (R-PA-11)· Later · Apr 7, 2025
  13. Rep. Dina Titus (D-NV-1)· Later · Apr 7, 2025
  14. Rep. Neal P. Dunn (R-FL-2)· Later · May 20, 2025
  15. Rep. Andrea Salinas (D-OR-6)· Later · May 20, 2025
  16. Rep. Dan Crenshaw (R-TX-2)· Later · Jun 12, 2025
  17. Rep. Adam Gray (D-CA-13)· Later · Jun 12, 2025
  18. Rep. Robert P. Bresnahan, Jr. (R-PA-8)· Later · Sep 30, 2025
Policy area
Health
Subjects
  • Health care costs and insurance
  • Medicare
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Feb 4, 2025
  2. HouseWays and MeansReferred Feb 4, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. ORPHAN Cures Act

    Display title, Short title · Introduced in House

  2. Optimizing Research Progress Hope And New Cures Act

    Short title · Introduced in House

  3. To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.

    Official title · Introduced in House